Yesterday, May 26, 2016, 107 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $0.02 to $20,083,643.73.

Highlighted Stocks Traded by Insiders:

Medidata Solutions (MDSO) - FREE Research Report

De Vries Glen Michael, who is President at Medidata Solutions, sold 7,500 shares at $45.00 on May 26, 2016. Following this transaction, the President owned 1.0 million shares meaning that the stake was reduced by 0.72% with the 7,500-share transaction.

Hirschfeld Steven Isaac, who is Vice Chairman at Medidata Solutions, sold 10,000 shares at $44.94 on May 26, 2016. Following this transaction, the Vice Chairman owned 110,166 shares meaning that the stake was reduced by 8.32% with the 10,000-share transaction.

Sherif Tarek, who is Chairman & CEO at Medidata Solutions, sold 7,500 shares at $45.00 on May 26, 2016. Following this transaction, the Chairman & CEO owned 914,349 shares meaning that the stake was reduced by 0.81% with the 7,500-share transaction.

The shares most recently traded at $43.10, down $1.90, or 4.41% since the insider transaction. Historical insider transactions for Medidata Solutions go as follows:

  • 4-Week # shares bought: 1,500
  • 4-Week # shares sold: 10,000
  • 12-Week # shares bought: 1,500
  • 12-Week # shares sold: 103,717
  • 24-Week # shares bought: 1,500
  • 24-Week # shares sold: 103,717

The average volume for Medidata Solutions has been 372,700 shares per day over the past 30 days. Medidata Solutions has a market cap of $2.6 billion and is part of the technology sector and computer software & services industry. Shares are down 12.25% year-to-date as of the close of trading on Thursday.

Medidata Solutions, Inc. provides cloud-based solutions for life sciences worldwide. The company offers applications and data analytics for clinical development. The company has a P/E ratio of 135.2. Currently, there are 8 analysts who rate Medidata Solutions a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MDSO - FREE

TheStreet Quant Ratings

rates Medidata Solutions as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, compelling growth in net income and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including premium valuation, weak operating cash flow and a generally disappointing performance in the stock itself. Get the full

Medidata Solutions Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

SP Plus (SP) - FREE Research Report

VCM STAN-CPC Holdings, LLC, who is Director at SP Plus, sold 35,500 shares at $22.55 on May 26, 2016. Following this transaction, the Director owned 701,787 shares meaning that the stake was reduced by 4.81% with the 35,500-share transaction.

The shares most recently traded at $22.37, down $0.18, or 0.82% since the insider transaction. Historical insider transactions for SP Plus go as follows:

  • 4-Week # shares sold: 100,000
  • 12-Week # shares sold: 100,000
  • 24-Week # shares bought: 20,000
  • 24-Week # shares sold: 151,538

The average volume for SP Plus has been 45,500 shares per day over the past 30 days. SP Plus has a market cap of $500.8 million and is part of the services sector and diversified services industry. Shares are down 6.9% year-to-date as of the close of trading on Thursday.

SP Plus Corporation provides parking management, ground transportation, and other ancillary services to commercial, institutional, and municipal clients in the United States, Puerto Rico, and Canada. The company has a P/E ratio of 23.9. Currently, there are 2 analysts who rate SP Plus a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SP - FREE

TheStreet Quant Ratings

rates SP Plus as a

buy

. The company's strengths can be seen in multiple areas, such as its good cash flow from operations and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

SP Plus Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Diebold (DBD) - FREE Research Report

Cox Phillip R, who is Director at Diebold, sold 3,534 shares at $24.00 on May 26, 2016. Following this transaction, the Director owned 25,054 shares meaning that the stake was reduced by 12.36% with the 3,534-share transaction.

The shares most recently traded at $24.74, up $0.74, or 2.99% since the insider transaction. Historical insider transactions for Diebold go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 419
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 419
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 1,349

The average volume for Diebold has been 706,200 shares per day over the past 30 days. Diebold has a market cap of $1.6 billion and is part of the technology sector and computer hardware industry. Shares are down 18.15% year-to-date as of the close of trading on Thursday.

Diebold, Incorporated provides financial self-service delivery, integrated services and software, and security systems primarily to the financial, commercial, retail, and other markets. The stock currently has a dividend yield of 4.75%. The company has a P/E ratio of 22.2. Currently, there are 2 analysts who rate Diebold a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on DBD - FREE

TheStreet Quant Ratings

rates Diebold as a

hold

. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, growth in earnings per share and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, weak operating cash flow and poor profit margins. Get the full

Diebold Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.